Aim: This study evaluates the association of total
erythrocyte, random platelet and apheresis platelet suspension given to
children receiving chemotherapy (CT) blocks with a diagnosis of acute
myeloblastic leukemia (AML) with the chemotherapy (CT) block the patient
received in that period.

Material and Methods: The transfusion need of a total of 146 patients
followed with a diagnosis of AML were determined as erythrocyte, random
platelet and platelet suspension as number and type in bags from the moment the
patients were diagnosed to the period the treatment ended by entering the blood
bank data base records.

Results: The number of total per patient average erythrocyte
use of a total of 37 patients during the process from the moment they were diagnosed to the period the
treatment ended was 27 (100-102). Of the CT blocks, the block in which both
erythrocyte and apheresis platelet use was the highest was Aie block. While the
average per person erythrocyte use was 8
(2-20) in this block, apheresis platelet use was found as 8,5 (1-28). While the
number of average per person random platelet use was 20 (7-139), the number of
average per person random platelet use was as 27 (1-102) in the Maintenance
block, which is the CT block in which the most random platelet was used.

Conclusion: In children with
AML, a great number of blood and blood product transfusions are needed
during CT. The efficiency of these transfusions can depend on a great number of
factors such as the type of acute leukemia, patient age, patient gender, the CT
block the patient is receiving, the CT drugs the patient is receiving in that
period and whether the patient has a clinical picture such as infection,
sepsis, intense consumption coagulopathy during that period. 

Keywords: Acute myeloblastic leukemia, child, chemotherapy, Transfusion, Blood